TPTX
Turning Point Therapeutics, Inc.
Glaxosmithkline Plc bought $5.8M of Turning Point Therapeutics, Inc.
Director and 10% owner
Bought$5,850,000
$18.00Price
325,000Shares
+19%Stake
What TPTX did for a copier
Prices for TPTX after this filing aren't in yet.
Glaxosmithkline Plc's record
3 other buys with 3 months of prices since 2017: on average +15.9% against the S&P 500, and 2 of 3 beat it.
We're building an app that can copy buys like this into your own brokerage. Join the waitlist
Traded Mon, Apr 22. Filed Wed, Apr 24, 7:28 PM ET, after the close. Not investment advice.